What Does Kisspeptin Do? The Signal Above GnRH

What does kisspeptin do? It switches on the neurons that release GnRH. Kisspeptin is a small peptide made in the hypothalamus, encoded by the KISS1 gene. It binds a receptor called KISS1R (legacy name GPR54) on GnRH neurons, those neurons fire, GnRH travels down the hypophyseal portal blood supply to the anterior pituitary, and the pituitary releases luteinizing hormone (LH) and follicle-stimulating hormone (FSH). Those two gonadotropins act on the ovaries or testes to drive sex-steroid production and gametogenesis. That places kisspeptin at the apex of the reproductive hormone cascade — an upstream signal, not a replacement hormone.

What does kisspeptin do in the hormone cascade?

Kisspeptin binds KISS1R on GnRH neurons and activates them. Inside the cell, receptor binding triggers phospholipase C, intracellular calcium mobilization, and membrane depolarization. The neuron fires, GnRH is released into portal blood, and the pituitary answers with LH and FSH. Nothing about the peptide is itself a sex hormone; it is the switch above them.

The gene was found in the wrong field. KiSS-1 was identified in 1996 as a melanoma metastasis-suppressor gene, and its peptide product was called metastin. The reproductive role arrived seven years later, when two groups independently traced normosmic hypogonadotropic hypogonadism in consanguineous families to loss-of-function mutations in GPR54 (de Roux 2003, PNAS 100(19):10972–6; Seminara 2003, NEJM 349(17):1614–27). Articles that date the discovery to "the early 2000s" are collapsing those two events; the gene is 1996, the reproductive function is 2003.

Kisspeptin neurons sit in two hypothalamic populations, and the species labels matter. The arcuate nucleus (ARC) population governs pulsatile secretion. The surge population lives in the anteroventral periventricular nucleus (AVPV) in rodents and in the preoptic area in primates — the same job, a different structure. In laboratory preparations, kisspeptin produces neuronal responses at picomolar concentrations, with in vitro work generally spanning picomolar to nanomolar; that sensitivity is why the system is described as an amplifier sitting at the top of the axis rather than a bulk hormonal input.

How a hormone pulse is built: the KNDy network

Arcuate kisspeptin neurons co-express two other peptides — neurokinin B (NKB) and dynorphin — which is why they are called KNDy neurons. As a reciprocally connected network they behave as the GnRH pulse generator, setting the timing of episodic kisspeptin release onto GnRH neurons, and so the timing of LH pulses. LH pulse frequency and amplitude are what downstream tissues read.

In the classical account, NKB starts each pulse and dynorphin provides the inhibitory feedback that ends it. That start/stop model is still the standard teaching version, though it is a simplification of what electrophysiology now describes; a 2025 review in Physiological Reviews covers the current model in detail (Koysombat 2025, Physiol Rev 105(2):707–764). Worth noting for anyone reading elsewhere: KNDy-as-pulse-generator is long-settled consensus, not a recent discovery, even where it is reported as breaking news.

The reason pulsatility is non-negotiable is that continuous stimulation of this axis shuts it down rather than driving it harder. That is the same pharmacology that makes continuous GnRH agonists suppressive, and it is why sustained kisspeptin exposure produces tachyphylaxis (see the LH and FSH section below). Any delivery strategy for a kisspeptin-receptor agonist has to reckon with it.

What kisspeptin does to LH and FSH

Kisspeptin administration raises both gonadotropins, but not equally: the LH response is substantially larger and faster than the FSH response. In six healthy men given a 90-minute intravenous infusion of kisspeptin-54, LH, FSH and testosterone all rose, and the peptide cleared with a half-life of 27.6 ± 1.1 minutes (Dhillo 2005, JCEM 90(12):6609–15).

The clearest human dose-response data comes from women with hypothalamic amenorrhea. In a randomized, double-blind, parallel-design study, twice-daily subcutaneous kisspeptin-54 at 6.4 nmol/kg or saline (n = 5 per group) ran for two weeks. On day one, the mean maximal increase within four hours of injection was 24.0 ± 3.5 IU/L for LH and 9.1 ± 2.5 IU/L for FSH. By the 14th injection day those responses had fallen to 2.5 ± 2.2 IU/L and 0.5 ± 0.5 IU/L respectively (p < 0.05 for both), while the pituitary still responded normally to GnRH — desensitization at the kisspeptin step, not pituitary failure (Jayasena 2009, JCEM 94(11):4315–23). That is the single most useful pharmacology result in the whole literature for anyone thinking about how this compound would be used.

Half-lives are quoted constantly and mis-attributed almost as often. The two figures usually printed side by side come from different species:

The "≈ 4 minutes" number attaches to kisspeptin-10, which is the form Promise dispenses, and it is a mouse measurement. Short duration in any species is the stated reason researchers have built longer-acting kisspeptin-receptor agonists.

Why the same hormone can suppress the axis or trigger a surge

Estrogen suppresses kisspeptin expression in the arcuate nucleus and stimulates it in the AVPV/preoptic population. Two nuclei, one hormone, opposite responses — that is the mechanism that produces both negative feedback across most of the cycle and the positive feedback that fires the preovulatory GnRH/LH surge.

The architecture exists because of a gap in the wiring. Kisspeptin neurons express estrogen receptors (principally ERα) and androgen receptors; GnRH neurons do not express ERα. Sex-steroid feedback therefore has nowhere to land except on kisspeptin neurons, which makes them an obligatory relay rather than an optional modulator.

In animal models, the AVPV/POA population becomes highly active during the preovulatory window, that activation depends on elevated estrogen, and it is necessary for the surge to occur. Disrupt kisspeptin signaling in those models and cyclicity, ovulation and reproductive competence go with it.

What the animal work shows, and what it does not

Mice lacking functional Kiss1 or Gpr54 signaling develop hypogonadism, fail to complete pubertal development, and — in males — show impaired sperm production and reduced testicular size. Females show anovulation. These are the phenotypes that established the requirement, and they are mouse phenotypes.

The most-cited PCOS result is also mouse-only, and it is the finding most often misread. In letrozole-treated KissCRE+/hM4Di female transgenic mice, hypothalamic kisspeptin neurons are hyperactivated, which may drive the elevated LH pulse frequency the model shows. Chemogenetic (DREADD) inhibition of those neurons in the same mouse model lowered the abnormally hyperactive LH pulse secretion and brought testosterone back to control levels, reversing the hyperandrogenemia (Coutinho 2024, Hum Reprod 39(9):2089–2103). No women were studied. It is a preclinical mouse model of PCOS, and it says nothing yet about what kisspeptin does in a person with PCOS.

The metabolic and stress inputs are animal work too. Caloric restriction reduces hypothalamic kisspeptin in research models; leptin administration restores kisspeptin expression and reproductive function in fasted animals, though leptin's action on kisspeptin neurons is largely indirect and direct leptin-receptor expression on these cells has been contested. Diet-induced obesity alters signaling in laboratory studies. On the stress side, glucocorticoids appear to suppress kisspeptin expression — a plausible mechanism for stress-induced reproductive suppression — chronic-stress models show reduced kisspeptin neuronal activity and altered gonadotropin patterns, and there is evidence of bidirectional communication with corticotropin-releasing hormone (CRH) neurons. Kisspeptin neurons also receive input from insulin and ghrelin signaling, which is why the system is described as the node where metabolic, stress and reproductive control converge, along with seasonal and circadian rhythms.

One thing not to carry out of the animal literature: dose. Published ranges quoted as "microgram quantities in rodents" and "milligram range in larger animals" come without a per-kilogram denominator, without a route, and often without a named species. They do not scale into a human dose and are not dosing guidance.

What human studies have measured

Beyond the genetics, the human dataset is small and specific. Kisspeptin rises substantially through the pubertal transition and is thought to awaken the GnRH network; inactivating KISS1R mutations cause failed puberty and activating mutations cause central precocious puberty. In functional hypothalamic amenorrhea (FHA), circulating kisspeptin has been reported as lower than in healthy controls — reported in review rather than established, traced to one small study, and qualified in the same group's later work as applying particularly to women with a reduced LH (Patel 2024, Ann N Y Acad Sci 1540(1):21–46).

Delivery is an active question. A randomized, double-blind, placebo-controlled crossover trial tested intranasal kisspeptin in healthy men, healthy women, and women with hypothalamic amenorrhoea; LH rose versus placebo in all three human groups at 12.8 nmol/kg, with a C57BL/6J male mouse arm for mechanism (Mills 2025, eBioMedicine 115:105689). The same paper reports the nasal formulation remaining stable for up to 60 days at 4 °C — that is shelf stability of the spray, not persistence in the body, and it should never be read as contradicting the minutes-long half-lives above. Separately, kisspeptin-54 has been given as a single subcutaneous injection (1.6–12.8 nmol/kg, n = 53) to trigger egg maturation in IVF protocols (Jayasena 2014, J Clin Invest 124(8):3667–77) — a different peptide form, in a monitored fertility-clinic protocol, and not something a prescription for compounded kisspeptin-10 reproduces.

Male reproduction is where the intuitive reading is wrong. In 52 men (17 fertile, 18 infertile with normal semen parameters, 17 infertile with abnormal parameters), serum kisspeptin was lower in the fertile group — 85.2 ± 20.5 ng/dL versus 109.4 and 108.7 ng/dL in the two infertile groups, p = 0.019 — while seminal plasma kisspeptin did not differ between groups at all (p = 0.48) (Parkpinyo 2025, J Assist Reprod Genet 42(11):3993–4002). More kisspeptin in serum did not track with better fertility; it tracked the other way. The study was single-center with n = 52, and the authors' own conclusion is that it requires further study — not a validated marker.

Kisspeptin and its receptor are also expressed outside the brain, in testicular tissue including Sertoli cells, spermatocytes and spermatozoa, which suggests local regulatory roles alongside central control. Seminal-fluid concentrations are described as substantially higher than serum, though published figures for that ratio are hard to pin down, and the seminal result above shows those levels carrying no fertile/infertile signal. A 2025 narrative review covers the fertility literature as a whole (Kotanidou 2025, J Clin Med 14(10):3284) — one review, not a body of new studies.

Why kisspeptin sits under Mood & Libido

Because a second, separate human literature exists, and it is brain-imaging work rather than fertility work. In 29 healthy heterosexual young men, kisspeptin administration compared with vehicle enhanced limbic brain activity in response to sexual and couple-bonding stimuli, correlated with psychometric measures of reward, drive and mood, and attenuated negative mood (Comninos 2017, J Clin Invest 127(2):709–719).

Two randomized, double-blind, placebo-controlled crossover trials followed in people with hypoactive sexual desire disorder (HSDD), both using a 75-minute intravenous kisspeptin-54 infusion at 1 nmol/kg/h against rate-matched placebo. In premenopausal women with HSDD (40 randomized, 32 completing both visits, mean age 29.2 years), kisspeptin modulated sexual and facial-attraction brain processing (Thurston 2022, JAMA Netw Open 5(10):e2236131). In men with HSDD (37 randomized, 32 completing, mean age 37.9 years), it modulated activity across the sexual-processing network on whole-brain analysis versus placebo (mean absolute change, Cohen d = 0.81; 95% CI, 0.41–1.21; P = .003) (Mills 2023, JAMA Netw Open 6(2):e2254313).

Read those results for what they are. The outcomes are brain activity and psychometric scores measured during an intravenous infusion of kisspeptin-54 in a research center — not a compounded kisspeptin-10 prescription, and not evidence of a durable effect on anyone's sex life. Kisspeptin is studied for this because it is the reproductive axis's own upstream signal, which makes it a different mechanism from the melanocortin pathway that PT-141 acts on. Both sit in the same Mood & Libido category for that reason and not because they work the same way.

What the trials report about side effects

Both randomized crossover trials used the same 75-minute intravenous kisspeptin-54 infusion (1 nmol/kg/h) against rate-matched placebo, and both reported tolerability. In premenopausal women with HSDD (32 completing both visits), the report states kisspeptin was well tolerated with no reported adverse effects (Thurston 2022). In men with HSDD (32 completing), it states kisspeptin was well tolerated, with no side effects or adverse events reported and no significant clinical effect on blood pressure or heart rate (Mills 2023). Both are single infusions in a research center, in small groups, measured over hours. The one repeat-dosing human study — twice-daily subcutaneous kisspeptin-54 for two weeks in women with hypothalamic amenorrhea (n = 5 per group) — reported loss of gonadotropin response rather than an adverse-event profile (Jayasena 2009). Neither describes repeated at-home use of compounded kisspeptin-10.

What kisspeptin does not do

It does not replace a hormone. Kisspeptin is upstream of GnRH, so it works only if the axis below it is intact and able to respond — which is a different proposition from supplying testosterone or estradiol directly, and it is the distinction most worth understanding before a visit.

It does not have an approved product behind it. There is no FDA-approved kisspeptin medication; what a pharmacy dispenses is a compounded preparation that is not FDA-approved.

It does not carry a validated blood test. Kisspeptin is measured in research assays, with no established clinical reference range, and the male-fertility study above shows how easily a level would be read backwards.

And the animal literature does not transfer as directly as it reads. Mouse PCOS models, knockout phenotypes, fasting and stress experiments describe the system's architecture. They are not results in people.

Where kisspeptin fits in a visit

Kisspeptin is prescription-only. A visit starts with an intake questionnaire covering your health history, current medications, and what you are hoping to address. A licensed provider reviews every request, decides whether kisspeptin is appropriate for you, and can decline — not everyone qualifies, and that clinical judgment is the point of the process rather than a formality. If a prescription is written, the medication is compounded by a licensed U.S. pharmacy and shipped to you as kisspeptin-10, a subcutaneous injectable; dose, frequency and duration are set by the prescriber and the pharmacy, never by figures published in animal studies.

Two things are worth bringing to that conversation. First, kisspeptin is upstream: it signals a hormone axis rather than supplying a hormone, so what it can do depends on the axis below it. Second, most of the detailed evidence is animal work, and the human trials measured hormone release and brain activity over hours in research settings. A provider can tell you what that means for your situation in a way an article cannot.

This article is for general education and is not medical advice, a diagnosis, or a treatment recommendation. Talk to a licensed clinician about your own health.